„ZUSAMMENARBEIT – Gesundheit“ und „Forschung zugunsten kleiner und mittlerer Unternehmen (KMUs)“

„ZUSAMMENARBEIT – Gesundheit“ und „Forschung zugunsten kleiner und

mittlerer Unternehmen (KMUs)“im 7. EU-Rahmenprogramm

Ylva Huber

Bereich Europäische und Internationale ProgrammeFFG – Österreichische Forschungsförderungsgesellschaft

Inhalt

• Das 7. Rahmenprogramm im Überblick

• Themen der ersten Ausschreibungen zu „Gesundheit“

• Forschung zugunsten kleiner und mittlerer Unternehmen (KMU)

Inhalt




Instrumente im 7. RP

7. EU-Rahmenprogramm 6. EU-Rahmenprogramm

Verbundprojekte („Collaborative Projects)

Integrierte Projekte (IP)

Gezielte Forschungsprojekte (STREPs)

Exzellenznetze (NoE) Exzellenznetze (NoE)

Koordinierungsmaßnahmen (CA) Koordinierungsmaßnahmen (CA)

Unterstützungsmaßnahmen (SSA) Unterstützungsmaßnahmen (SSA)

Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)

Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)

Einzelprojekte im ERC (Programm Ideas)KMU spezifische Maßnahmen KMU spezifische Maßnahmen

Artikel 169 Artikel 169

ERA-NET und ERA-NET PLUS ERA-NET

Gemeinsame Technologieinitiativen (JTI)

25. Februar 2005 Präsentationstitel der FFG 6

Die Ausschreibungen sind geöffnet!

rp7.ffg.at

Inhalt




Ziele: Verbesserung der Gesundheit der europäischen Bevölkerung Stärkung der europ. Industrie/Firmen

im Bereich Gesundheit Blick auf globale Gesundheitsfragen

(z.B. Epidemien

Schwerpunkte: Translationale Forschung (Grundlagenforschung klinische

Anwendung) Neue Therapien (Entwicklung und Validierung) Methoden zur Gesundheitsförderung, Krankheitsprävention Diagnostische Instrumente und medizinische Technologien Effiziente Gesundheitssysteme

Thema 1- Gesundheit

(6.050 Mio. Euro)

Thema 1: Gesundheit

(6.050 Mio. €)

Einreichfrist 1. Ausschreibung: 19. April 2007Einreichfrist 2. Ausschreibung: 18. September 2007

Biotechnology, generic tools and technologies for human health1

Translating research for human health 2

Optimising the delivery of health care to European Citizens3

Other Actions across the Health Theme4

High-throughput research

Unifying human and model organism genetic variation databases Temporal and spatial proteomics to study biological processes relevant to

human health Groundbreaking techniques for DNA sequencing and genotyping 2. Call: SME-driven collaborative research projects for developing tools and technologies for high-

throughput research

Detection, Diagnosis and Monitoring Development of a hybrid imaging system Novel optical methodologies for detection, diagnosis and monitoring of disease or

disease-related processes Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of response to

therapy In vivo image-guidance for cell therapy 2. Call : Standardisation and improvement of pre-analytical procedures for in vitro diagnostics High throughput molecular diagnostics in individual patients for genetic diseases with

heterogeneous clinical presentation

Biotechnology, generic tools and technologies for human health (1)1

Predicting suitability, safety and efficacy of therapies

Thema zum Großteil durch Innovative Medicines Initiative (IMI) abgedeckt!

Novel alternative testing strategies for use in pharmaceutical discovery and development

Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development

Promotion, development, validation, acceptance and implementation of QSARs (quantitative structure-activity relationship) for toxicology

Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

In silico modelling for ADMET outcomes


Innovative therapeutic approaches and interventions Development and production of new generation antibodies Innovative approaches for the development of vaccines for young children Immunotherapy of human food allergies

2.Call:

Development of emerging gene therapy tools and technologies for clinical application

Stem cell lines for cell-based therapies. Development of stem cell culture conditions. Stem cells for kidney regeneration. Adding value to EU stem cell therapy research: scientific communication and

future perspectives.


Large-scale data gathering

Networking biobanking initiatives across Europe: developing standards and norms for existing and future human sample biobanks

Molecular epidemiological studies in existing well characterised European (and/or other) population cohorts

Comparative studies of genetic variation in humans: towards a reference population in Europe

Characterisation and variability of the microbial communities in the Human Body Structure-function analysis of membrane-transporters and channels for the

identification of potential drug target sites High throughput analysis of lipids and lipid-protein interactions Genome-wide association studies in mammalian non-rodent models for the

identification of genes relevant to human health and disease

Translating research for human health (1)2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES

LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY 2

Systems biology

A system approach to eukaryotic unicellular organism biology Modelling of T-cell activation Fundamental approaches to stem cell differentiation Developing an integrated in vitro, in vivo and systems biology modelling approach to

understanding apoptosis in the context of health and disease

2. call:

Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and diseases

Coordination and Support Actions in large-scale data gathering and systems biology Traditional Chinese Medicine in post-genomic era. Specific International

Cooperation Action. Targeted region: China.

Translating research for human health (2)2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES

LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY 2

Brain and related diseases

Stroke and mechanisms underlying ischemic brain damage Coding in neuronal assemblies Neurobiology of anxiety disorders Memory loss: underlying mechanisms and therapy From basic spinal mechanisms to spinal cord disease and trauma. Neuron-glia interactions in health and disease

2. Call:

Restorative approaches for therapy of neurodegenerative diseases. From mood disorders to experimental models. Neuronal mechanisms of vision and related diseases. Childhood and adolescent mental disorders. Specific International Cooperation

Action. Target regions: Eastern Europe and Central Asia and Western Balkans.

Translating research for human health (3) 2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN

DEVELOPMENT AND AGEING2

Human Development and Ageing

Novel approaches to reconstitute normal immune function at old age. Termination of developmental processes and their reactivation in adult life Biomarkers of ageing. Increasing the participation of elderly in clinical trials. Research on human development and/or healthy ageing across the EU

Translating research for human health (4)2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN

DEVELOPMENT AND AGEING2

Anti-microbial drug resistance including fungal pathogens

2. Call: Novel targets for drugs against Gram negative bacteria. Host-pathogen interactions in infections by Streptococcus pneumoniae. An integrated platform for development and clinical evaluation of point-of-care

diagnostic devices for microbial detection, antibiotic susceptibility determination and biomarkers

Molecular epidemiology to control nosocomial and community spreading of highly virulent multi-drug resistant strains of bacterial pathogens.

Health and economic cost of antimicrobial resistance. Conference on genetic and biochemical tools for postgenomic physiological analysis

of Staphylococcus, in particular MRSA.

Translating research for human health (5) 2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:

TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH2

HIV, AIDS, malaria and tuberculosis

HIV/AIDS Drug Discovery and Preclinical Development Highly innovative approaches for research into host-pathogen interaction in tuberculosis Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria

and tuberculosis and of latent tuberculosis infection (LTBI). Addressing knowledge gaps in pregnancy malaria. New HIV Vaccines inducing broadly-reactive neutralising antibodies.

2. Call:

Network on HIV and anti-HIV drug resistance HIV and Hepatitis co-infection Blocking the transmission of malaria: the mosquito vector target. European network for study and clinical management of TB drug resistance. Support platform for the development of PRD vaccines Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and

European partners. (SICA, Targeted Region: India) Coordination of European research activities with global initiatives, including Public-Private-

Partnerships (SICA; Targeted Regions: ICPC). Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious

diseases (SICA; Targeted Regions: ICPC).



Potentially new and re-emerging epidemics

Development of broadly protective influenza vaccine candidates. Identifying immunological mechanisms of protection for influenza vaccines Standardisation of immunological assays including surrogate markers for evaluation of new

influenza vaccines in clinical trials Innovative point-of-care diagnostic tests for influenza. Development of additional treatment strategies for patients suffering from highly pathogenic

influenza. Development of pandemic influenza containment and mitigation strategies. Supporting highly innovative inter-disciplinary research on influenza. Influenza research in collaboration with Asian partners. (SICA, Targeted regions: Asia)

2. Call:

Strengthening research on prediction, identification, modelling and surveillance of newly emerging infectious diseases in humans.

Definition of research needs and priorities in Europe in the area of Emerging Infectious Epidemics.



Cancer• Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel

diagnosis and therapy strategies.

• Translating clinical ’omics’-technology (genomics, proteomics, metabolomics) into innovative cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer patients.

• Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer.

• Novel cancer screening methods.

• Optimising research on end of life care of cancer patients.

• Understanding and fighting metastasis.

• Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy

• Developing high-throughput bioassays and models for human cancers in lower species.

2. Call:

• Innovative combination clinical trials for multimodal cancer therapy.

• Role of inflammation in tumour initiation and progression.

• Epidemiology of gene-environment interactions involved in carcinogenesis.

• Translating the hypoxic tumour microenvironment.

• ERA-NET on optimisation of the use of cancer registries for cancer research purposes

• Studying cancer aetiology in Latin America. (SICA)

Translating research for human health (8)TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES2

Cardiovascular Disease

Molecular basis of the inflammatory response and associated vascular remodelling in arteriosclerosis.

Vascular remodelling in aneurysmal disease. Combating stroke.

2. Call: Congenital pathologies affecting the heart. Cell therapies for the treatment of heart ischemia. Organ imaging in CVD. Integrating pharmacogenomic approaches into the treatment of CVD.

Translating research for human health 9)TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES2

Diabetes and Obesity

Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention. Combined forms of diabetes in children.

Insulin resistance as a key factor in the development of diabetes and metabolic syndrome. Pathophysiological mechanisms related to excess fat.

A road-map for diabetes research.

2. Call:

Nutritional signals and the development of new diabetes/obesity therapeutic agents. Markers and treatment for diabetic neuropathy complications. Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects. Use of beta cell imaging in diabetes mellitus.


Rare Diseases

Natural course and pathophysiology of rare diseases. Research capacity-building in the field of rare diseases.

Other Chronic Diseases

Osteoarthritis. Inflammatory bowel disease. Osteoporosis: signalling pathways in bone formation and homeostasis. Genetic factors of Osteoporosis. Intervertebral disc degeneration: prevention and repair. Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD). Hearing impairment and degeneration. Impairment of touch and proprioception at old age. Visual impairment and degeneration.

2. Call: Understanding and combating age-related muscle weakness. Translational research aiming for a treatment of urinary incontinence. Early processes in the pathogenesis of chronic inflammatory diseases.


Translating clinical research into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and health therapies and technologies

2.call:

Implementation of research into healthcare practice Self-medication and patient safety Patient Safety Research Network Improving clinical decision making Better use of medicines. Continuity of clinical care. Patient self-management of chronic disease.

Quality, solidarity and sustainability of health systems

2.call:

Evaluation of disease management programmes Health systems and long term care of the elderly Mobility of health professionals Health care human resource planning in nursing. Clinician working time and patient safety. Health outcome measures and population ageing. Trends of population health European system of Diagnosis-related groups (DRG)

Optimising the delivery of health care to European Citizens (1)3

Enhanced health promotion and disease prevention

2.call: Promoting healthy behaviour in children and adolescents Interventions addressing the gradient of health inequalities Public health interventions addressing the abuse of alcohol. Evaluation of suicide prevention strategies across and within European countries. Improve vaccination coverage

Horizontal Coordination and Support Actions across “Optimising the Delivery of Health Care to European Citizens

2.call: Disease networks of centres of reference. Effectiveness of health investments. Patient mobility and access to information. Brokering research into policy. A road-map for ageing research. Health Services Research conference Mental health research conference. Public Health intervention research conference


Specific International Cooperation Actions for Health System Research

2.call: Epidemiological investigations into long-term trends of population health as

consequence of socio-economic transitions, including life-style induced health problems. SICA (Mediterranean Partner countries, Russia, Eastern European and Central Asia)

Universal and equitable access to health care and health financing. SICA (MCP, ACP, Asia and Latin America)

Health care intervention research – optimising hospital care. SICA (Western Balkans.)

Health care intervention research – improving pre-natal and maternal care. SICA (ACP and Mediterranean Partner Countries)


Coordination and Support Actions across the Theme • Reinforcing the network of National Contact Points (NCP) for the Seventh Framework Programme

under Health Theme by promoting transnational co-operation.)

• Promoting participation of high-technology research intensive SMEs, operating in the biomedical engineering and other medical technology sectors´relevant to Health Theme.

• Assessment and valorisation of project outcome for hightechnology and research intensive SME participating to Framework Programmes of Research in the healthcare sector.

• Science communication actions.

• Initiatives to foster dialogue and debate on health research issues of interest to the public.• Studies on the impact of EU legislation on health research and related developments and

applications.

2.call:

• Promotion and facilitation of international cooperation in areas relevant to the objectives of this theme. (SICA, ICPC)

Responding to EU policy needs (2.call)

Paediatric medicinal products, Drug safety research, Living and work conditions, Health statistics, Tobacco Control

Other Actions across the Health Theme4

Technologieplattformen und Gemeinsame Technologieinitiativen

• Mobilisierung europäischer Ressourcen im Bereich Forschung, technologische Entwicklung und Innovation durch Zusammenbringen aller Akteure eines definierten Forschungsbereiches (Industrie, KMU, Universitäten, Endverbraucher)

• Industriegetrieben

• Gemeinsame Definition und Erstellung einer strategischen Forschungsagenda (mittel- bis langfristig)

= Input zur Entwicklung der thematischen Programme im 7. RP

• Einige wenige werden als Gemeinsame Technologieinitiativen (Joint Technology Initiatives) etabliert

• Neuer Weg zur Realisierung von public-private partnerships auf EU-Ebene mit definierter rechtlicher Struktur

Example „Innovative Medicines“ - en route to a „Joint Technology Initiative“

Accelerated Development of safe and more effective medicines

Revitalization of the the biopharmaceutical research and development (R&D) environment for Europe to become more competitive

Improving the collaboration between all relevant actors from public and private organisations (public-private partnerships)

Draft and Implementation of a European Research Agenda:

Second version of the Strategic Research Agenda published recently

First Calls expected for end of 2007/beginning of 2008

http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed

http://rp7.ffg.at/RP7.aspx_param_target_is_116120.v.aspx

« Innovative Medicines »

2. version of the « Strategic Research Agenda »:

4 main topics:

Safety: Early safety evaluation and risk assessment, creation of a European

Centre for Drug Safety

Efficacy: Predictive pharmacology, biomarker identification and validation, patient

recruitment and risk assessment

Knowledge Management: New technologies to control and analyse enormous quantities of

information in an integrative and predictive way

Education and Training: Bridge gaps in expertise required to strengthen the biopharmaceutical

R&D process, creation of a European Medicines Research Academy

Technologieplattform « Innovative Medicines »

Contact in Austria:

Univ. Prof. Dr. Hans Georg Eichler, Vice Rector of the Medical University in Vienna [email protected]

mailto:[email protected]

Relevante Themen der 1.Ausschreibungen aus anderen Bereichen

Food, Agriculture, Fisheries and Biotechnology: e.g. Fork to farm: Food (including seafood), health and well being

Information and Communication Technologies: Objective ICT-2007.5.3: Virtual Physiological Human

Nanosciences, Nanotechnologies, Materials and new ProductionTechnologies:„Creation of a critical and commented database on the health, safety and environmental impact of nanoparticles“„Substantial innovation in the European medical industry: development ofnanotechnology-based systems for in-vivo diagnosis and therapy (in Coordination with topic HEALTH-2007-2.4.1-7 and HEALTH-2007-1.2-3 in Theme 1 "Health")

Environment: Environment and Health

Security: Topic SEC-2007-1.3-05 Water distribution surveillance; Critical Infrastructure Protection

Inhalt





Zusammenarbeit zwischen Industrie und F&E-Dienstleistern

• Forschung zugunsten von Kleinen und Mittleren Unternehmen (KMUs)

• Forschung zugunsten von KMU-Verbänden


Kennzeichen

• Themen: Bottom up –Ansatz (gesamtes Feld der Wissenschaft & Technologie)

• KMUs/KMU-Verbände lagern Forschung & technologische Entwicklung aus

• Flexibilität bezüglich der intellectual property rights


Aktivitäten

• Forschungs- und technologische Entwicklungsaktivitäten

• Demonstrationsaktivitäten

• Andere Aktivitäten (Trainings, dissemination activities)

• Management-Aktivitäten


Research for SMEs

at least 3 SMEs from

at least 3 countries (MS, AS)

at least 2 universitiesresearch centresindustrial companies research performing SMEs

Project participation scheme

IndustryRTD-performers


Research for SMEs/SME-Associations

Research for SMEs Research for SME associations

Duration 1 - 2 years 2 - 3 years

Number of partners 5 - 10 10 -15

Total budget* € 0.5 – 1.5 Million € 1.5 – 4 Million

Activities R&D, demonstration, management, other activities

R&D, demonstration, management, other activities

* Share of R&D carried out by RTD performers : ≥ 60%Source: European Commission


Einreichfristen:

• Research for SMEs: FP7-SME-2007-1 Einreichfrist: 4.September 200

• Research for SME Associations: FP7-SME-2007-2 Einreichfrist: 1. Juni 2007

• Kontakt: Dr. Ines Haberl, [email protected]

http://rp7.ffg.at/RP7.aspx http://cordis.europa.eu/en/home.html


http://rp7.ffg.at/RP7.aspx

Page 41/45 Y.Huber / FFG-EIP

Wichtige Dokumente zur Vorbereitung:

Arbeitsprogramme + Annexes Guide for Applicants Rules for Participation Model Grant Agreement

Leitfaden/Formular für Anbahnungsfinanzierung:

rp7.ffg.at -> „Services der FFG“

Page 42/45 Y.Huber / FFG-EIP

Kontaktieren Sie uns!

Ihre Ansprechpartner für Life Sciences in der FFG/Bereich Europäische und InternationaleProgramme

Mag. Birgit Steininger

Leiterin des Referats für Biowissenschaften,

Nationale Kontaktstelle für Lebensmittel, Landwirtschaft und Biotechnologie (DW 4101)

[email protected]

Dr. Ylva Huber

Nationale Kontaktstelle für Gesundheit (DW 4102)

[email protected]

Dr. Ines Haberl

Nationale Kontaktstelle für KMUs (DW 4103)

[email protected]

e-mail: [email protected], Tel: +43/57755-Durchwahl





Vielen Dank für Ihre Aufmerksamkeit &

viel Erfolg für Ihre Projekte im 7. Rahmenprogramm!

Documents

„ZUSAMMENARBEIT – Gesundheit“ und „Forschung zugunsten kleiner und mittlerer Unternehmen (KMUs)“